Greece will make concessions to repay its loans and remain in the EU, resulting in a 5% surge in the USA markets and boosting energy prices, while regarding the effect on Magnum Hunter Resources: "Houston We Have Liftoff."
My estimation is based upon the 3 Year Chart and volatility. Taking into account the plummet which occurred in January of 2012, this makes my guessing speculation estimation challenging, otherwise my calculation would be in the lower half of that range. The results are dependent upon good news from the Roth Conference 2015 which takes place next week.
I expect that my fellow Longs are in agreement with this assessment.
I estimate that this sell off at the beginning of trade today was ignited by misinterpretation of information posted at clinical trials website regarding AEZS 108 and fueled by near term profit taking.
The Company's Chairman and CEO, David Dodd , will be presenting a corporate overview and update at the 27th Annual Roth Conference on Wednesday, March 11, 2015 , at 11:00 am (Pacific), in the Colonnade Room (Track 4) of the Ritz-Carlton Laguna Niguel Hotel, in Dana Point, California .
The reason that I know this is because for the first time since I bought the stock, today I considered selling my shares to buy another stock. I have held this company stock for more than a year and I am basically even. In the past when I have felt that a particular investment was essentially 'dead money' and I subsequently sold my shares, often times the trade immediately backfired as the equity that I sold sickeningly skyrocketed.
I just stopped service with my phone. I had nothing but problems will their billing cycle. The company representatives are abusive egocentric idiots. I hate this company with a passion.
I have been with Yahoo Finance Message Boards for a long time and there is nothing unusual about this one in comparison to the others.
A hostile takeover cannot be stopped by a poison pill. It is only a maneuver to slow down the process and give time for management to negotiate for a golden parachute.
Shorts are practically non-existent with the figure at 0.6% of the total floats as of January 15, 2015, with the short interest being a tiny 424,955 shares.
Net proceeds from the Offering are expected to be approximately US$34.5 million, after deducting underwriting commissions and other expenses related to the Offering. The Company intends to use the net proceeds from the Offering to make the US$5.7 million payment to the holders of warrants in connection with the warrant amendment agreements described above, to continue to fund ongoing drug development activities, for the potential addition of commercialized products to the Company's pipeline, and for general corporate purposes, for working capital and to fund negative cash flow.
Zogenix did not develop Zohydro. In 2010 Zogenix bought the right to market Zohydro in the United States from Elan. The following year Alkermes which makes Vivitrol bought a unit of Elan that included Zohydro abd the deal included the existing agreement with Zogenix.
My fellow Longs know what I am talking about.
Sabby Healthcare Master Fund, Ltd.